Chief Scientific Officer · OCULAR THERAPEUTIX, INC (OCUL)

Jeffrey Heier

FY2024 is the first fiscal year CompBrief holds for Jeffrey Heier as a named executive officer of OCULAR THERAPEUTIX; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$6,599,173

Salary $365,064Stock awards $3,875,988Bonus $220,000

4th of 5 named executive officers at Ocular Therapeutix by FY2024 total.

5 named officers on file for OCULAR THERAPEUTIX, FY2024

Jeffrey Heier’s pay file — $29

  • 1 fiscal year of pay, line by line
  • OCUL’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how OCULAR THERAPEUTIX’s whole pay program stands against its peers

  • OCULAR THERAPEUTIX’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on OCUL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Jeffrey Heier’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Jeffrey Heier compensation by year

OCULAR THERAPEUTIX Summary Compensation Table · the one fiscal year held
In US dollars, as OCULAR THERAPEUTIX reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$365,064
Bonus$220,000
Stock awards$3,875,988
Option awards$2,116,553
Non-equity incentive$0
Pension and deferred compensation$0
All other$21,568
Total$6,599,173

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: OCULAR THERAPEUTIX, INC DEF 14A filed April 29, 2025, accession 0001558370-25-005868, and prior-year filings. Open the filing on EDGAR.

How this page was built: the OCULAR THERAPEUTIX, INC filed document, accession 0001558370-25-005868. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU100,000$854,000—
RSU91,666$782,828—
Option6,334—$4.25
Option366,666—$9.70
Option191,667—$9.31

Per the Outstanding Equity Awards at Fiscal Year-End table in OCULAR THERAPEUTIX, INC's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

10 Form 4 lines since the FY2024 proxy (filed April 29, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-10-02Sale10b5-110,869$7.05307,457
2026-08-24Sale10b5-13,296$10.78318,326
2026-05-26Sale10b5-13,018$8.20320,350
2026-02-23Sale10b5-13,057$8.28323,368
2026-01-02Grant or award derivative—240,932$0.00240,932
2026-01-02Grant or award—79,112$0.00326,425
2025-11-24Sale10b5-13,469$12.04245,940
2025-10-02Sale10b5-110,502$11.04249,409

The 8 most recent of 10 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

OCULAR THERAPEUTIX’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Pravin DugelExecutive Chair, President and Chief Executive Officer (3)$18,574,830
Antony MattessichFormer President and Chief Executive Officer$8,782,364
Peter KaiserChief Development Officer$6,629,358
Jeffrey Heier · this pageChief Scientific Officer$6,599,173
Donald NotmanChief Operating Officer and Chief Financial Officer$2,069,341

Board service

OCULAR THERAPEUTIX board · FY2021–FY2023
Director compensation in US dollars, as OCULAR THERAPEUTIX reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2023$55,000$63,720$180,021$31,162$329,903
FY2022$55,000$30,640$106,538$29,875$222,053
FY2021$55,000—$164,158—$219,158

Each year as the company reported it in OCULAR THERAPEUTIX's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: OCULAR THERAPEUTIX pays directors a $50,000 cash retainer. As stated in OCULAR THERAPEUTIX's FY2023 proxy.

Committees

Nominating/Governance

The full OCULAR THERAPEUTIX compensation record

free company brief

This page is one person within OCULAR THERAPEUTIX's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the OCULAR THERAPEUTIX proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are OCULAR THERAPEUTIX's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jeffrey Heier's compensation dossier · One-time report. No refunds.